The Hong Kong Junk Drawer: Ignore the Noise and Follow the Cash FlowGlobal Report·17 hours ago83690+1.97%02575+7.61%
Inside the Fringes of HKEX: Tencent's RMB Counter and Overhauls in Non-Mainstream EquitiesGlobal Report·19 hours ago02570+0.77%80700+0.84%
We're Not Very Worried About Xuanzhu Biopharmaceutical's (HKG:2575) Cash Burn RateSimplywall·Aug 19 at 06:41 PM02575+7.61%
A Microcosm of Transition: How a Diverse Slate of Hong Kong Companies Navigates a Shifting EconomyGlobal Report·Aug 18 at 04:44 AM096800.00%02575+7.61%
Hong Kong's Fragmented Signals: From Property Defense to Tech Capital RaisingsGlobal Report·Aug 11 at 04:43 AM06098-0.09%02575+7.61%
Hong Kong Mid-Caps Diverge: Biotech Expands Margins as Property Services Pivot to DefenseGlobal Report·Aug 5 at 04:13 AM01666+1.73%02497-0.84%
The Unbundling of Hong Kong's Equities: Value Chains in Specialized Tech and IndustrialsGlobal Report·Jul 30 at 04:13 AM084000.00%02302+3.19%
Xuanzhu Biopharma ordered to pay RMB 9.33 million in CIETAC arbitration awardPUBT·Jul 19 at 05:49 AM02575+7.61%
Sihuan’s Xuanzhu Wins NMPA NDA Acceptance for New Reflux Esophagitis Use of AnaprazoleTip Ranks·Jun 29 at 11:38 PM00460+1.15%02575+7.61%
Xuanzhu Biopharma says NMPA accepts NDA for anaprazole sodium in reflux esophagitisPUBT·Jun 29 at 11:05 PM02575+7.61%
Xuanzhu Biopharma Advances Anaprazole into Phase III Trial for H. pylori EradicationTip Ranks·Jun 21 at 05:38 AM02575+7.61%
